Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets

por Jack, Dominic, Nolting, Axel, Galazka, Andrew
Publicado 2020

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update

por Jack, Dominic, Damian, Doris, Nolting, Axel, Galazka, Andrew
Publicado 2021

Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update

por Jack, Dominic, Damian, Doris, Nolting, Axel, Galazka, Andrew
Publicado 2021

Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine

por Hermann, Robert, Krajcsi, Peter, Fluck, Markus, Seithel-Keuth, Annick, Bytyqi, Afrim, Galazka, Andrew, Munafo, Alain
Publicado 2021

Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions

por Hermann, Robert, Krajcsi, Peter, Fluck, Markus, Seithel-Keuth, Annick, Bytyqi, Afrim, Galazka, Andrew, Munafo, Alain
Publicado 2021

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review

por Rammohan, Kottil, Coyle, Patricia K., Sylvester, Elke, Galazka, Andrew, Dangond, Fernando, Grosso, Megan, Leist, Thomas P.
Publicado 2020

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety

por Giovannoni, Gavin, Galazka, Andrew, Schick, Regina, Leist, Thomas, Comi, Giancarlo, Montalban, Xavier, Damian, Doris, Dangond, Fernando, Cook, Stuart
Publicado 2020

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets

por Giovannoni, Gavin, Coyle, Patricia K., Vermersch, Patrick, Walker, Bryan, Aldridge, Julie, Nolting, Axel, Galazka, Andrew, Lemieux, Caroline, Leist, Thomas P.
Publicado 2021

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies

por De Stefano, Nicola, Sormani, Maria Pia, Giovannoni, Gavin, Rammohan, Kottil, Leist, Thomas, Coyle, Patricia K, Dangond, Fernando, Keller, Birgit, Alexandri, Nektaria, Galazka, Andrew
Publicado 2021

Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study

por Freedman, Mark S, Coyle, Patricia K, Comi, Giancarlo, L Scarberry, Susan, Damian, Doris, Hyvert, Yann, Dangond, Fernando, Galazka, Andrew, Jack, Dominic, Lebson, Lori A, Leist, Thomas P
Publicado 2021